EMA update on review of valsartan

NDMA – is classified as a probable human carcinogen which, based on results from laboratory tests, may cause cancer with long-term use.

there is no immediate risk and patients taking valsartan are advised not to stop their treatments unless they have been advised to do so by their pharmacist or doctor.